Journal article
A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A).
Abstract
TPS2673
Authors
Ellis PM; Taylor SK; Bradbury PA; Goffin JR; Juergens RA; Laurie SA; Liu G; Spratlin JL; Chau NG; Charpentier D
Journal
Journal of Clinical Oncology, Vol. 41, No. 16_suppl, pp. tps2673–tps2673
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 1, 2023
DOI
10.1200/jco.2023.41.16_suppl.tps2673
ISSN
0732-183X